Psilocybin Treatment Investigation: OCD & Other Conditions Including Lyme

GlobalData reported 10.28.2023, “Psilocybin by Ceruvia Lifesciences for Obsessive-Compulsive Disorder: Likelihood of Approval.” Ceruvia Lifesciences focuses on development of neuro-transformational medicines to treat neurological and psychiatric disorders. Psilocybin is a tryptamine alkaloid which is a psychedelic compound that targets 5hydroxytryptamine 1A and 2A. Formulated as a capsule, it is being developed to be administered orally.

In addition to obsessive compulsive disorder which is in phase two of clinical development, psilocybin is being investigated by Ceruvia Lifesciences as a drug candidate for treating several diseases and conditions including: Lyme disease, alcohol use disorder, nicotine dependence, cluster headache syndrome, and migraine headaches. 


For More Information

Read GlobalData Report

Read Additional LDA Articles on Psilocybin Treatment